Cell proliferation in ovarian carcinoma: Superior accuracy of S-phase fraction (SPF) by DNA labeling index versus flow cytometric SPF, lack of independent prognostic power for SPF and DNA ploidy, and limited effect of SPF on tumor growth rate

Gynecologic Oncology

Volumn 81, Issue 3, 2001, Pages 466-476

  Meyer, John S ^a   Gersell, Deborah Jo ^b   Yim, Stephen ^a  

^a ST LUKE S HOSPITAL   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Border line; Bromodeoxyuridine; Carcinoma; Cell kinetics; DNA; Flow cytometry; Growth rate; High grade; Ki 67; Low malignant potential; MIB 1; Ovary

Indexed keywords

BROXURIDINE; CELL DNA; KI 67 ANTIGEN; MONOCLONAL ANTIBODY KI 67; THYMIDINE;

ARTICLE; CANCER CLASSIFICATION; CANCER GRADING; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; CARCINOSARCOMA; CELL CYCLE S PHASE; CELL KINETICS; CELL LOSS; CELL PROLIFERATION; DISEASE COURSE; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; LABELING INDEX; MAJOR CLINICAL STUDY; OVARY CARCINOMA; PATHOLOGY; PLOIDY; PRIORITY JOURNAL; PROGNOSIS; TUMOR GROWTH;

EID: 0034988636     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.2001.6184     Document Type: Article

References (59)

1. Prediction of long-term survival by flow cytometric analysis of cellular DNA content in patients with advanced ovarian cancer
2. Analysis of PCP-data to determine the fraction of cells in the various phases of cell cycle
3. Thymidine labeling index, flow cytometric S-phase measurement, and DNA index in human tumors
4. Multiparametric deoxyribonucleic acid cell cycle analysis of breast carcinomas by flow cytometry
5. Die bedeutung der PCNA-proliferationsfraktion für die prognose des ovarialkarzinoms
6. Different calculation methods for flow cytometric S-phase fraction: Prognostic implications in breast cancer?
7. Micropapillary serous carcinoma of the ovary: A distinctive low-grade carcinoma related to serous border-line tumors
8. Ovarian serous borderline tumors with micropapillary and cribriform patterns: A study of 40 cases and comparison with 44 cases without these patterns
9. Pseudomyxoma peritonei: New concepts in diagnosis, origin, nomenclature, and relationship to mucinous borderline (low malignant potential) tumors of the ovary
10. Peritoneal implants of ovarian serous borderline tumors: Histologic features and prognosis
11. In vitro labeling of solid tissues with tritiated thymidine for autoradiographic detection of S-phase nuclei
12. Cell kinetics of human tumors by in vitro bromodeoxyuridine labeling
13. FIGO stage, histologic grade, age, and race as prognostic factors in determining survival for cancers of the female gynecological system: An analysis of 1973-87 SEER cases of the cervix, ovary, vulva, and vagina
14. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: Three-year results
15. Implications of biochemical, cytokinetic, pharmacologic, and toxicologic relationships in the design of optimal therapeutic schedules
16. What might we expect when animals or humans bearing different cancers with widely different growth and regrowth rates are treated with the same drug or drugs delivered in the same and different ways?
17. Regrowth resistance in cancer: Why has it been largely ignored?
18. Prognostic significance of DNA index, multiploidy, and S-phase fraction in ovarian cancer
19. Oncogene expression in ovarian cancer: A pilot study of c-myc oncoprotein in serous papillary ovarian cancer
20. Ki 67 expression in 35 borderline ovarian tumors: Relations with clinicopathologic parameters and ploidy
21. Clinical significance of abnormal nuclear DNA content in serous ovarian tumors
22. Dual-parameter flow cytometric analysis coupling the measurements of forward-angle light scatter and DNA content of archival ovarian carcinomas of low malignant potential
23. The role of DNA flow cytometry in borderline malignant ovarian tumors
24. Intratumoral DNA heterogeneity correlated with lymph node involvement and surgical staging in epithelial ovarian cancer by flow cytometry
25. Cell kinetics: A prognostic marker in epithelial ovarian cancer
26. Cell kinetics in ovarian cancer: Relationship to clinicoopathologic features, responsiveness to chemotherapy, and survival
27. Cell kinetics by bromodeoxyuridine labeling and deoxyribonucleic acid ploidy in prostatic carcinoma needle biopsies
28. S-Phase fraction and nuclear size in long term prognosis of patients with breast cancer
29. S-Phase fractions of colorectal carcinomas related to pathologic and clinical features
30. Cell cycle parameters and prognosis of colorectal cancer
31. On the growth rates of human malignant tumors: Implications for medical decision making
32. Cytokinetic definition of acute and chronic breast cancer
33. In vivo cell kinetics in head and neck squamous cell carcinomas predicts local control and helps guide radiotherapy regimen
34. Cell proliferation measurements by bromodeoxyuridine or thymidine incorporation: Clinical correlates
35. Monoclonal antibodies Ki-S3 and Ki-S5 yield new data on the 'Ki-67' proteins
36. Prognostic significance of Ki-67 and topoisomerase IIα expression in infiltrating ductal carcinoma of the breast: A multivariate analysis of 863 cases
37. Autoradiographic analysis of cell proliferation in spontaneous breast cancer of C3H mouse. III. Growth fraction
38. Positivity of the proliferation marker Ki-67 in noncycling cells
39. Nuclear distribution of the Ki-6 antigen during the cell cycle: Comparison with growth fraction in human breast cancer cells
40. Tritiated thymidine labelling in vitro of human cancer of the breast: Counting error and sampling error
41. Steroid receptors and Ki-67 reactivity in ovarian cancer and in normal ovary: Correlation with DNA flow cytometry, biochemical receptor assay, and patient survival
42. Direct comparison of bromodeoxyuridine and Ki-67 labelling indices in human turnouts
43. Comparison of mitotic index, in vitro bromodeoxyuridine labeling, and MIB-1 assays to quantitate proliferation in breast cancer
44. Immunologic proliferation marker Ki-S2 as prognostic indicator for lymph node-negative breast cancer
45. Immunohistochemical detection of the ras oncogene product p21 in advanced ovarian cancer: Lack of correlation with clinical outcome
46. Tumor DNA content as a prognostic feature in advanced epithelial ovarian carcinoma
47. Klinischer verlauf des ovarialkarzinoms in abhangigkeit von morphologischen prognosefactoren und zellkinetischen paramietern
48. Prognostic value of the flow cytometric DNA index in human ovarian carcinoma
49. Flow-cytometric prognostic factors for the survival of patients with ovarian carcinoma: A 5-year follow-up study
50. Flow cytometric analysis of DNA content in human ovarian cancers
51. Cytofluorometric analysis of the DNA content in ovarian carcinoma and its relationship to patient survival
52. Flow cytometric evaluation of epithelial ovarian cancer
53. The prognostic significance of nuclear DNA content in malignant epithelial tumors of the ovary
54. Tumor DNA ploidy and prognosis of patients with serous cystadenocarcinoma of the ovary
55. Ki-67 immunostaining and DNA flow cytometry as prognostic factors in epithelial ovarian cancers
56. Cell dynamics of undifferentiated carcinomas of the ovary: Immunohistochemical estimation of their growth fraction and apoptotic status
57. The combined evaluation of p53 accumulation and of Ki-67 (MIB 1) labelling index provides independent information on overall survival of ovarian carcinoma patients